Wells Fargo & Company MN decreased its position in shares of LivaNova PLC (NASDAQ:LIVN) by 9.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 358,341 shares of the company’s stock after selling 36,785 shares during the period. Wells Fargo & Company MN owned 0.74% of LivaNova worth $28,638,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Cerebellum GP LLC bought a new stake in shares of LivaNova during the fourth quarter worth $128,000. Pillar Pacific Capital Management LLC bought a new stake in shares of LivaNova in the fourth quarter valued at about $208,000. Shelton Capital Management bought a new stake in shares of LivaNova in the third quarter valued at about $209,000. Affinity Investment Advisors LLC bought a new position in LivaNova in the fourth quarter worth about $211,000. Finally, Crossmark Global Holdings Inc. bought a new position in LivaNova in the third quarter worth about $263,000. 85.52% of the stock is owned by institutional investors and hedge funds.
LivaNova PLC (NASDAQ:LIVN) traded up $0.94 during trading on Wednesday, hitting $88.38. The company had a trading volume of 311,875 shares, compared to its average volume of 402,536. LivaNova PLC has a 12-month low of $48.16 and a 12-month high of $92.31. The stock has a market capitalization of $4,286.29, a P/E ratio of 25.14, a PEG ratio of 2.77 and a beta of 0.75. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.79 and a current ratio of 2.14.
LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, February 28th. The company reported $0.88 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.78 by $0.10. LivaNova had a positive return on equity of 9.37% and a negative net margin of 2.10%. The company had revenue of $278.40 million during the quarter, compared to analysts’ expectations of $278.48 million. During the same period in the previous year, the firm posted $0.83 earnings per share. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. research analysts expect that LivaNova PLC will post 3.2 EPS for the current fiscal year.
A number of equities research analysts have recently weighed in on LIVN shares. Canaccord Genuity boosted their price target on LivaNova from $76.00 to $81.00 and gave the stock a “hold” rating in a research note on Tuesday, February 27th. BidaskClub lowered LivaNova from a “buy” rating to a “hold” rating in a research report on Saturday. Needham & Company LLC reissued a “buy” rating and issued a $104.00 price target (up from $97.00) on shares of LivaNova in a report on Wednesday, February 28th. Zacks Investment Research downgraded LivaNova from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 25th. Finally, ValuEngine raised LivaNova from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $81.43.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $82.15, for a total value of $82,150.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 3,000 shares of company stock valued at $246,270. 0.28% of the stock is owned by company insiders.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.